2D phase contrast MRI reveals changes in uterine arterial blood flow in pregnant women administrated tadalafil for fetal growth restriction-Reference-Cited by-同舟云学术

2D phase contrast MRI reveals changes in uterine arterial blood flow in pregnant women administrated tadalafil for fetal growth restriction

Published:2023-07-10 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Nii Masafumi¹,Enomoto Naosuke¹,Ishida Masaki¹,Magawa Shoichi¹,Takakura Sho¹,Maki Shintaro¹,Tanaka Kayo¹,Toriyabe Kuniaki¹,Tanaka Hiroaki¹,Kondo Eiji¹,Sakuma Hajime¹,Ikeda Tomoaki¹

Affiliation:

1. Mie University School of Medicine

Abstract

Abstract We aimed to examine the effect of uterine arterial (UtA) blood flow changes after tadalafil treatment for fetal growth restriction (FGR) using two-dimensional (2D) phase-contrast magnetic resonance imaging (PC-MRI). We recruited 14 pregnant women with FGR who were aged 20–44 years, at ≥ 20 weeks’ gestation, between May 2019 and July 2020. They underwent 2D PC-MRI for UtA blood flow measurement 3 days (interquartile range: 2–4) after diagnosis. This group (FGR group) was compared with 14 gestational age (GA)-matched healthy pregnant women (control group). Six patients in the FGR group received treatment with tadalafil administered at 20 mg twice daily after the first MRI until delivery. They underwent a second MRI 1 week later. The median total UtA blood/body surface area was 420 mL/min/m2 (290–494) in the FGR group and 547 mL/min/m2 (433–681) in the control group (p = 0.01). Percent increase of blood flow in the FGR and control groups were significantly different at 68.8% (51–75) and 18.8% (16.0–57), respectively (p < 0.01). UtA blood flow in pregnant women with FGR was significantly lower than that in healthy pregnant women. Tadalafil is expected to improve UtA blood flow, thereby improving placental function in pregnant patients with FGR.

Publisher

Research Square Platform LLC

Reference36 articles.

1. 1. Say, L., Gülmezoglu, A. M. & Hofmeyr, G. J. Maternal nutrient supplementation for suspected impaired fetal growth. Cochrane Database Syst. Rev. CD000148 (2003).

2. 2. Salafia, C. M. et al. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. Am. J. Obstet. Gynecol. 173, 1049–1057 (1995).

3. 3. Melamed, N. et al. FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction. Int. J. Gynaecol. Obstet. 152 Suppl 1(Suppl 1), 3–57 (2021).

4. 4. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics and the Society for Maternal-Fetal Medicine. ACOG Practice Bulletin No. 204: Fetal Growth Restriction. Obstet. Gynecol. 133, e97–e109 (2019).

5. 5. Pels, A., Beune, I. M., van Wassenaer-Leemhuis, A. G., Limpens, J. & Ganzevoort, W. Early-onset fetal growth restriction: A systematic review on mortality and morbidity. Acta Obstet. Gynecol. Scand. 99, 153–166 (2020).